Diabetes Care, Vol 15, Issue 6 773-784, Copyright © 1992 by American Diabetes Association

ARTICLES

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

JE Foley
Diabetes Department, Sandoz Research Institute, Sandoz Pharmaceutical Corporation, East Hanover, New Jersey 07936.

There are elevated fatty acid levels in non-insulin-dependent diabetes mellitus that are due to diminished insulin action in inhibiting fatty acid release from adipocytes. Insulin therapy and other inhibitors of fatty acid release from adipocytes (e.g., nicotinic acid) suppress these elevated fatty acid levels and bring about a reduction in hyperglycemia. One mechanism by which fatty acids may be causal in hyperglycemia is in stimulating gluconeogenesis in the liver in the postabsorptive state. Another mechanism is in attenuating glucose disposal in skeletal muscle in the fed state. Potential nonglycemia-related effects of fatty acids are in substrate utilization in the heart and lipid synthesis in the liver. Inhibition of fatty acid oxidation is useful in reducing hyperglycemia by inhibiting glucose production in humans. However, there is less evidence that such inhibition can be useful in increasing glucose utilization in muscle, as predicted by the Randle hypothesis. This, coupled with potential adverse effects on heart muscle, make liver targeting of fatty acid oxidation inhibitors an important factor in their potential for development. Although such agents have advantageous effects on lipid metabolism, overdosing can lead to adverse liver lipid effects via the same mechanism. These adverse liver lipid effects could be minimized by development of reversible inhibitors that allow fatty acid oxidation to occur only during the overnight fast. The potential usefulness of such agents is evident; however, no drug that meets these objectives has been developed.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Duivenvoorden, B. Teusink, P. C. N. Rensen, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol Acute inhibition of hepatic {beta}-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity J. Lipid Res., May 1, 2005; 46(5): 988 - 993. [Abstract] [Full Text] [PDF]

				M. Lehtihet, N. Welsh, P.-O. Berggren, G. A. Cook, and A. Sjoholm Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E438 - E446. [Abstract] [Full Text] [PDF]

				A. Cabrero, M. Merlos, J. C. Laguna, and M. V. Carrera Down-regulation of acyl-CoA oxidase gene expression and increased NF-{kappa}B activity in etomoxir-induced cardiac hypertrophy J. Lipid Res., February 1, 2003; 44(2): 388 - 398. [Abstract] [Full Text] [PDF]

				J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes Endocr. Rev., October 1, 2002; 23(5): 599 - 622. [Abstract] [Full Text] [PDF]

				C. Kohl, D. Ravel, J. Girard, and J.-P. Pegorier Effects of Benfluorex on Fatty Acid and Glucose Metabolism in Isolated Rat Hepatocytes: From Metabolic Fluxes to Gene Expression Diabetes, August 1, 2002; 51(8): 2363 - 2368. [Abstract] [Full Text] [PDF]

				K. Tordjman, K. N. Standley, C. Bernal-Mizrachi, T. C. Leone, T. Coleman, D. P. Kelly, and C. F. Semenkovich PPAR{alpha} suppresses insulin secretion and induces UCP2 in insulinoma cells J. Lipid Res., June 1, 2002; 43(6): 936 - 943. [Abstract] [Full Text] [PDF]

				A. Szewczyk and L. Wojtczak Mitochondria as a Pharmacological Target Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127. [Abstract] [Full Text] [PDF]

				N. F. Brown, R. S. Mullur, I. Subramanian, V. Esser, M. J. Bennett, J.-M. Saudubray, A. S. Feigenbaum, J. A. Kobari, P. M. Macleod, J. D. McGarry, et al. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme J. Lipid Res., July 1, 2001; 42(7): 1134 - 1142. [Abstract] [Full Text] [PDF]

				R. L. Dobbins, L. S. Szczepaniak, B. Bentley, V. Esser, J. Myhill, and J. D. McGarry Prolonged Inhibition of Muscle Carnitine Palmitoyltransferase-1 Promotes Intramyocellular Lipid Accumulation and Insulin Resistance in Rats Diabetes, January 1, 2001; 50(1): 123 - 130. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				N. B. Ruderman, A. K. Saha, D. Vavvas, and L. A. Witters Malonyl-CoA, fuel sensing, and insulin resistance Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E1 - E18. [Abstract] [Full Text] [PDF]

				E. A. van Schaick, K. P. Zuideveld, H. E. Tukker, M. W. E. Langemeijer, A. P. Ijzerman, and M. Danhof Metabolic and Cardiovascular Effects of the Adenosine A1 Receptor Agonist N6-(p-Sulfophenyl)Adenosine in Diabetic Zucker Rats: Influence of the Disease on the Selectivity of Action J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 21 - 30. [Abstract] [Full Text]

				R. O. Deems, R. C. Anderson, and J. E. Foley Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1998; 274(2): R524 - R528. [Abstract] [Full Text] [PDF]

				V. Esser, N. F. Brown, A. T. Cowan, D. W. Foster, and J. D. McGarry Expression of a cDNA Isolated from Rat Brown Adipose Tissue and Heart Identifies the Product as the Muscle Isoform of Carnitine Palmitoyltransferase I (M-CPT I) J. Biol. Chem., March 22, 1996; 271(12): 6972 - 6977. [Abstract] [Full Text] [PDF]

				N. F. Brown, B. C. Weis, J. E. Husti, D. W. Foster, and J. D. McGarry Mitochondrial Carnitine Palmitoyltransferase I Isoform Switching in the Developing Rat Heart J. Biol. Chem., April 14, 1995; 270(15): 8952 - 8957. [Abstract] [Full Text] [PDF]

				V. N. Jackson, J. M. Cameron, F. Fraser, V. A. Zammit, and N. T. Price Use of Six Chimeric Proteins to Investigate the Role of Intramolecular Interactions in Determining the Kinetics of Carnitine Palmitoyltransferase I Isoforms J. Biol. Chem., June 23, 2000; 275(26): 19560 - 19566. [Abstract] [Full Text] [PDF]